IOncology

Recently, the team led by Dr. Jiuda Zhao at the Breast Disease Diagnosis and Treatment Center of Qinghai University Affiliated Hospital published their latest research findings in the Journal of Clinical Oncology (JCO), with an impact factor of 42.10. This study is the first to combine the current standard triple antiemetic therapy with electroacupuncture (EA) to address chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients. The results demonstrate that adding EA to the standard triple antiemetic regimen significantly enhances CINV treatment outcomes. This study stands as the highest-impact acupuncture-related research publication in the field of oncology in China, showcasing the scientific prowess and innovative capabilities of Chinese scholars on the international stage. Oncology Frontier invited Dr. Jiuda Zhao to discuss this groundbreaking study.

The 2024 Annual Meeting of the European Society for Medical Oncology (ESMO) was recently held in Barcelona, Spain. As one of the top international conferences in the field of oncology, it gathered experts and scholars from around the world to share the latest research findings and explore future development directions. During this conference, several landmark studies in the field of hematologic malignancies were presented, providing valuable insights and references for current clinical practice and future research. Hematology Frontier invited Dr. Annarita Conconi from the University of Eastern Piedmont in Italy, one of the Chairs of the Mini Oral Session on Hematologic Malignancies, to comment on these landmark studies and to look ahead at the future trends in hematologic oncology.

The 2024 International Liver Cancer Association (ILCA) Conference recently held its highly anticipated awards ceremony in Rio de Janeiro, Brazil. This event attracted attention from liver cancer researchers worldwide, recognizing those who made significant contributions to the field over the past year. The ceremony aimed to further promote global collaboration and innovation in liver cancer research.

From September 26 to 28, 2024, the China Anti-Cancer Association (CACA) and the CACA Integrative Esophageal Cancer Committee hosted the 2024 CACA Integrative Esophageal Cancer Academic Conference in Hefei. This prestigious event gathered leading experts in the field of esophageal cancer from China and abroad. The topics ranged from cancer prevention, early diagnosis and treatment, standardized therapy, and integrated treatment approaches. Oncology Frontier had the opportunity to interview Dr. Renquan Zhang from The First Affiliated Hospital of Anhui Medical University (AMU) to discuss advancements in the diagnosis and treatment of esophageal cancer. Below is a summary of the interview for our readers.